Plain-English translation of NCT05515770 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing cabotegravir (CAB-LA), a long-acting injectable medication given as a shot to help prevent HIV infection. Instead of taking a daily pill, participants receive injections on a regular schedule. The study focuses on young people ages 18–30 who were assigned male at birth and are at higher risk of HIV infection.
Many people in Brazil at risk for HIV have started taking daily oral preventive medication, but many stop using it because they forget doses or face other challenges. This medication aims to offer a simpler option—fewer, longer-lasting injections instead of daily pills—to make HIV prevention easier and more accessible.
You likely qualify if…
You likely don't qualify if…
You would visit a study clinic to receive injections of the medication on a scheduled basis (typically every one to two months). You would also have regular blood tests to check your HIV status, liver function, and overall health. The study involves multiple visits over time, and you would need to stay in the same area during the study period to continue participating.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Brazil